Close
Using our own immune cells to target and kill cancer
Researchers at MyAV·¶ are pioneering groundbreaking cancer treatments which reprogramme the patient’s own immune system to recognise and kill cancerous cells.
CAR T-cell therapies are developed by harvesting T-cells, a type of lymphocyte, from a patient’s blood and genetically re-engineering them outside the body, so that they can recognise and destroy cancer cells.Ìý
This reprogramming is achieved by introducing a gene for an artificial protein called a chimeric antigen receptor, or CAR for short.
Using the body’s immune system to fight cancer avoids some of the common side effects of conventional therapies, as non-cancerous cells are not targeted by the t-cells.
Dr Martin Pule’s laboratory at the MyAV·¶ Cancer Institute is leading the way in developing new CAR T-cell therapies and MyAV·¶ currently ranks top in Europe and second in the world for the number of inventions and patent applications in relation to this revolutionary treatment
In addition, MyAV·¶â€™s CAR T-cell programme, which involves researchers at the MyAV·¶ Cancer Institute and clinicians at MyAV·¶H and GOSH, is the largest in Europe. This ‘cancer campus’ currently has 10 clinical trials open which use technology developed at MyAV·¶.
Other key researchers include Professor Emma Morris (MyAV·¶ Division of Infection and Immunity), Dr Claire Roddie (MyAV·¶ Cancer Institute and MyAV·¶H), Professor Karl Peggs (MyAV·¶H), Professor Persis Amrolia (MyAV·¶ GOS Institute of Child Health and GOSH) and Dr Sara Ghorashian (MyAV·¶ GOS Institute of Child Health and GOSH).Ìý
MyAV·¶â€™s CAR T-cell therapies recently featured in the BBC2 documentary ‘War in the Blood’, which followed two patients on their treatment journey over two years.
The programme is supported by the National Institute for Health Research (NIHR), the ÌýBiomedical Research Centre (RC) and funded by partners including the blood cancer charity Bloodwise and the EU 7th Framework Programme.
The CAR T-cell field is becoming increasingly commercialized with considerable contributions to the field being made by industry. The MyAV·¶ CAR T-cell programme has a track record of collaborating with industry.
Meet the team
Links
Image
- Dr Martin Pule and Dr Claire Roddie of MyAVᦉ۪s CAR T-cell programme